中国P站

MicroRNAs; Endometrial Cancer; Pathogenesis; Biomarkers; Therapeutics; Tumor Microenvironment; Chemoresistance; Epigenetic Regulation; Prognostics; Gene Expression

Introduction

MicroRNAs (miRNAs) are integral to the pathogenesis and progression of endometrial cancer (EC), orchestrating gene expression that influences crucial cellular processes [1].

Their dysregulation is implicated across various stages of EC, impacting cellular proliferation, apoptosis, invasion, and metastasis, positioning them as significant research targets in gynecologic oncology for potential diagnostic and therapeutic applications [1].

Specific miRNAs exhibit distinct roles in EC; for instance, miR-200c and the let-7 family function as tumor suppressors, while miR-21 and miR-155 act as oncogenes, highlighting the necessity of understanding these varied functions for targeted treatment strategies [2].

Analyzing miRNA expression profiles offers valuable prognostic information and can assist in differentiating between endometrial cancer subtypes, potentially guiding clinical management by identifying miRNAs associated with increased recurrence or metastasis risk [3].

Epigenetic modifications are frequently the driving force behind miRNA dysregulation in EC, suggesting that understanding these mechanisms could unveil novel therapeutic avenues aimed at reversing oncogenic miRNA activity [4].

The potential of certain miRNAs as circulating biomarkers for the early detection and monitoring of EC is being actively explored, owing to their stability in biofluids like serum and urine, which renders them promising candidates for non-invasive diagnostic tools [5].

Investigational therapeutic strategies targeting specific miRNAs in EC are progressing, encompassing miRNA mimics to reinstate tumor suppressor functions and anti-miRs to inhibit oncogenic miRNAs, thereby introducing a novel treatment paradigm [6].

The intricate interaction between miRNAs and the tumor microenvironment in EC significantly influences disease progression, with miRNAs modulating stromal cells, immune cells, and the extracellular matrix, thereby impacting metastatic potential [7].

Identifying the specific molecular targets of miRNAs is paramount to deciphering their oncogenic or tumor-suppressive roles in EC, as elucidating the downstream genes they regulate offers critical insights into the involved molecular pathways [8].

The association of certain miRNAs with chemoresistance in EC presents a formidable challenge to effective treatment, yet research into miRNA modulation holds promise for overcoming these resistance mechanisms and enhancing patient outcomes [9].

Functional studies utilizing EC models are indispensable for validating the roles of miRNAs and for the preclinical development of miRNA-based therapies, providing a deeper understanding of complex regulatory networks and therapeutic potential [10].

Description

MicroRNAs (miRNAs) play a crucial role in the development and advancement of endometrial cancer (EC) by regulating gene expression. The dysregulation of specific miRNAs is associated with various stages of EC, affecting cellular proliferation, apoptosis, invasion, and metastasis. Their potential as diagnostic biomarkers, prognostic indicators, and therapeutic targets makes them a significant research area in gynecologic oncology [1].

This review emphasizes specific miRNAs with distinct roles in endometrial cancer; for example, miR-200c and the let-7 family function as tumor suppressors, whereas miR-21 and miR-155 act as oncogenes. Understanding these differential functions is vital for developing targeted treatment strategies [2].

Investigating miRNA expression profiles can aid in distinguishing between different subtypes of endometrial cancer, providing prognostic value. Certain miRNAs are linked to a higher risk of recurrence or metastasis, which can inform clinical management decisions [3].

The dysregulation of miRNAs in endometrial cancer is frequently driven by epigenetic modifications. Understanding these underlying mechanisms may open up new avenues for therapeutic intervention, potentially by reversing oncogenic miRNA activity [4].

Several miRNAs have emerged as potential circulating biomarkers for the early detection and monitoring of endometrial cancer. Their inherent stability in biofluids such as serum and urine makes them attractive candidates for non-invasive diagnostic purposes [5].

Therapeutic strategies that specifically target miRNAs are currently under investigation for endometrial cancer. These approaches include the use of miRNA mimics to restore tumor suppressor function or anti-miRs to inhibit oncogenic miRNAs, representing a novel therapeutic strategy [6].

The interplay between miRNAs and the tumor microenvironment in endometrial cancer is complex and influences disease progression. miRNAs can modulate stromal cells, immune cells, and the extracellular matrix, thereby impacting the metastatic process [7].

Research into the specific targets of miRNAs is essential for a comprehensive understanding of their oncogenic or tumor-suppressive functions in endometrial cancer. Identifying the downstream genes regulated by dysregulated miRNAs offers valuable insights into the molecular pathways involved in the disease [8].

The association between certain miRNAs and chemoresistance in endometrial cancer poses a significant challenge for treatment. However, research focused on miRNA modulation could potentially overcome these resistance mechanisms, leading to improved patient outcomes [9].

Functional studies conducted in endometrial cancer models are critical for validating the roles of miRNAs and for the preclinical development of miRNA-based therapies. These studies help to elucidate intricate regulatory networks and assess therapeutic potential [10].

Conclusion

MicroRNAs (miRNAs) are critical regulators in endometrial cancer (EC), influencing proliferation, apoptosis, invasion, and metastasis. Specific miRNAs act as tumor suppressors (e.g., miR-200c, let-7 family) or oncogenes (e.g., miR-21, miR-155). miRNA expression profiling aids in subtype differentiation and prognostication. Epigenetic modifications drive miRNA dysregulation, offering therapeutic targets. Circulating miRNAs are being explored as non-invasive biomarkers for early detection and monitoring. Therapeutic strategies involve miRNA mimics and anti-miRs. miRNAs also interact with the tumor microenvironment, impacting progression. Identifying miRNA targets is crucial for understanding their roles and molecular pathways. MiRNA dysregulation is linked to chemoresistance, a challenge for treatment. Functional studies are vital for validating miRNA roles and developing therapies.

References

1. Luo, T, Yang, L, Wang, Y. (2022) .Int J Mol Sci 23:23(12):6789.

   , ,

2. Guo, C, Zhang, Y, Wang, J. (2021) .Cancers 13:13(19):4871.

   , ,

3. Li, S, Zhou, W, Zhang, Y. (2023) .Gynecol Oncol 168:168:55-62.

   , ,

4. Wang, P, Liu, Y, Zhao, J. (2020) .Epigenetics 15:15(11):1161-1174.

   , ,

5. Tan, J, Sun, Y, Wang, X. (2022) .Front Oncol 12:12:887654.

   , ,

6. Kim, M, Park, S, Lee, J. (2021) .J Gynecol Oncol 32:32(3):e34.

   , ,

7. Chen, D, Wang, L, Zhang, H. (2023) .Cells 12:12(5):765.

   , ,

8. Jiang, W, Li, Y, Guo, S. (2020) .Mol Cancer 19:19(1):110.

   , ,

9. Yao, Y, Zhu, H, Li, X. (2022) .Exp Cell Res 421:421(2):113363.

   , ,

10. Zhang, J, Wang, F, Liu, P. (2023) .Pharmacol Res 187:187:106570.

    , ,